Skip to content
10-Q

Quarterly Report

INOZYME PHARMA, INC.

0000950170-24-121090

← back to feed
Filed
Nov 5, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 29, 2024 64.24M sh
Shares Diluted Q3 2024 · Sep 30, 2024 63.28M sh
Shares Diluted Q3 2024 · Sep 30, 2024 62.33M sh
Shares Diluted Q3 2024 · Sep 30, 2023 56.76M sh
Shares Diluted Q3 2024 · Sep 30, 2023 48.49M sh
Capex Q3 2024 · Sep 30, 2024 $45K
Capex Q3 2024 · Sep 30, 2023 $193K
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$72.72M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$52.19M
Long Term Debt Q3 2024 · Sep 30, 2024 $42.07M
Long Term Debt Q3 2024 · Dec 31, 2023 $44.77M
Short Term Debt Q3 2024 · Sep 30, 2024 $3.58M
Short Term Investments Q3 2024 · Sep 30, 2024 $107.03M
Short Term Investments Q3 2024 · Dec 31, 2023 $154M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $24.58M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $34.59M
Cash And Equivalents Q3 2024 · Sep 30, 2023 $46.9M
Stockholders Equity Q3 2024 · Sep 30, 2024 $82.79M
Stockholders Equity Q3 2024 · Jun 30, 2024 $94.42M
Stockholders Equity Q3 2024 · Mar 31, 2024 $118.84M
Stockholders Equity Q3 2024 · Dec 31, 2023 $140.48M
Stockholders Equity Q3 2024 · Sep 30, 2023 $160.21M
Stockholders Equity Q3 2024 · Jun 30, 2023 $105.59M
Stockholders Equity Q3 2024 · Mar 31, 2023 $103.35M
Stockholders Equity Q3 2024 · Dec 31, 2022 $118.39M
Current Liabilities Q3 2024 · Sep 30, 2024 $18.34M
Current Liabilities Q3 2024 · Dec 31, 2023 $14.69M
Total Liabilities Q3 2024 · Sep 30, 2024 $60.57M
Total Liabilities Q3 2024 · Dec 31, 2023 $60.37M
Current Assets Q3 2024 · Sep 30, 2024 $140.94M
Current Assets Q3 2024 · Dec 31, 2023 $196.25M
Total Assets Q3 2024 · Sep 30, 2024 $143.36M
Total Assets Q3 2024 · Dec 31, 2023 $200.85M
Eps Diluted Q3 2024 · Sep 30, 2024 −$0.39
Eps Diluted Q3 2024 · Sep 30, 2024 −$1.20
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.29
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.02
Eps Basic Q3 2024 · Sep 30, 2024 −$0.39
Eps Basic Q3 2024 · Sep 30, 2024 −$1.20
Eps Basic Q3 2024 · Sep 30, 2023 −$0.29
Eps Basic Q3 2024 · Sep 30, 2023 −$1.02
Sga Expense Q3 2024 · Sep 30, 2024 $4.96M
Sga Expense Q3 2024 · Sep 30, 2024 $16.1M
Sga Expense Q3 2024 · Sep 30, 2023 $4.73M
Sga Expense Q3 2024 · Sep 30, 2023 $15.97M
Rd Expense Q3 2024 · Sep 30, 2024 $19.89M
Rd Expense Q3 2024 · Sep 30, 2024 $60.76M
Rd Expense Q3 2024 · Sep 30, 2023 $13.34M
Rd Expense Q3 2024 · Sep 30, 2023 $36.86M
Net Income Q3 2024 · Sep 30, 2024 −$24.57M
Net Income Q3 2024 · Sep 30, 2024 −$74.95M
Net Income Q3 2024 · Jun 30, 2024 −$27.03M
Net Income Q3 2024 · Mar 31, 2024 −$23.35M
Net Income Q3 2024 · Sep 30, 2023 −$16.64M
Net Income Q3 2024 · Sep 30, 2023 −$49.63M
Net Income Q3 2024 · Jun 30, 2023 −$15.58M
Net Income Q3 2024 · Mar 31, 2023 −$17.4M
Operating Income Q3 2024 · Sep 30, 2024 −$24.85M
Operating Income Q3 2024 · Sep 30, 2024 −$76.86M
Operating Income Q3 2024 · Sep 30, 2023 −$18.07M
Operating Income Q3 2024 · Sep 30, 2023 −$52.84M